Assertion: IDNA therapeutic are better than similar products isolated from non-human sources. Re

step 1 So in this question we have, in this question we have assertion R -D -N -A, R -D -N -A, Thera, t

Assertion: IDNA therapeutic are better than similar products...

Key Concepts

Recombinant DNA Therapeutics

Recombinant DNA therapeutics are pharmaceutical products developed by inserting human genes into host cells, which then produce proteins that mimic natural human molecules. This process, based on genetic engineering, ensures that the resulting drugs are structurally similar and functionally equivalent to endogenous human proteins, enhancing their efficacy and safety in clinical use.

Immunogenicity

Immunogenicity is the propensity of a substance to provoke an immune response. In therapeutics, minimizing immunogenicity is crucial because unwanted immune reactions can reduce drug effectiveness and cause adverse effects. Products that closely resemble natural human proteins, such as those made by recombinant DNA technology, are less likely to trigger harmful immune responses.

Genetic Engineering

Genetic engineering involves modifying an organism's genetic material to achieve desired traits or produce specific products. In the context of therapeutics, genetic engineering is applied to create recombinant proteins that are identical to human counterparts, thereby enhancing drug safety and consistency compared to proteins derived from non-human sources.

Comparative Biologic Production

Comparative biologic production examines the differences between producing therapeutic agents via recombinant DNA technology and extracting them from non-human sources. This comparison is important because recombinant products typically offer advantages such as reduced immunogenicity, improved reproducibility, and better patient compatibility, leading to more favorable clinical outcomes.

Transcript

Please give Ace some feedback